Literature DB >> 2487540

Double-blind study on the interaction of oxaprozin with metoprolol in hypertensives.

A Halabi1, M Linde, H Zeidler, J König, W Kirch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2487540     DOI： 10.1007/bf01858116

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN： 0920-3206            Impact factor:   3.727


× No keyword cloud information.
  5 in total

1.  Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin.

Authors:  J Watkins; E C Abbott; C N Hensby; J Webster; C T Dollery
Journal:  Br Med J       Date:  1980-09-13

2.  Effects of indomethacin alone and during diuretic or beta-adrenoreceptor-blockade therapy on blood pressure and the renin system in essential hypertension.

Authors:  J A Lopez-Ovejero; M A Weber; J I Drayer; J E Sealey; J H Laragh
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

3.  Interaction between oxprenolol and indomethacin on blood pressure in essential hypertensive patients.

Authors:  A Salvetti; F Arzilli; R Pedrinelli; P Beggi; M Motolese
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

4.  A multicentre double-blind comparison of oxaprozin aspirin therapy on rheumatoid arthritis.

Authors:  J A Hubsher; I M Ballard; B R Walker; J A Gold
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

5.  The influence of prostaglandin inhibition by indomethacin on blood pressure and renal function in hypertensive patients treated with cilazapril.

Authors:  W Kirch; K Stroemer; J F Hoogkamer; C H Kleinbloesem
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335
  5 in total
  3 in total

Review 1.  NSAIDs and blood pressure. Clinical importance for older patients.

Authors:  A G Johnson
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 2.  NSAIDs and increased blood pressure. What is the clinical significance?

Authors:  A G Johnson
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

Review 3.  Clinical pharmacokinetics of oxaprozin.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-12       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.